Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase i study

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 2, 2011, Pages 283-290

  Zheng, Y ^a   Scheerens, H ^a   Davis, J C ^a   Deng, R ^a   Fischer, S K ^a   Woods, C ^a   Fielder, P J ^a   Stefanich, E G ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN M ANTIBODY; MTRX 1011A; RHEUMATOID FACTOR; TRX 1; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; FEMALE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPECIES DIFFERENCE; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; ARTHRITIS, RHEUMATOID; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MODELS, BIOLOGICAL; PAPIO; RECEPTORS, FC; TRANSLATIONAL RESEARCH;

EID: 78951478220     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.311     Document Type: Article

References (32)

1. Ng, C.M., Stefanich, E., Anand, B.S., Fielder, P.J. & Vaickus, L. Pharmacokinetics/ pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm. Res. 23, 95-103 (2006).
2. Burton, D.R. & Dwek, R.A. Immunology. Sugar determines antibody activity. Science 313, 627-628 (2006).
3. Chao, D.T., Ma, X., Li, O., Park, H. & Law, D. functional characterization of N297a, A murine surrogate for low-fc binding anti-human CD3 antibodies. Immunol. Invest. 38, 76-92 (2009).
4. Isaacs, J.D., Clark, M.R., Greenwood, J. & Waldmann, H. Therapy with monoclonal antibodies. an in vivo model for the assessment of therapeutic potential. J. Immunol. 148, 3062-3071 (1992).
5. Lund, J. et al. Multiple binding sites on the CH2 domain of IgG for mouse fc gamma R11. Mol. Immunol. 29, 53-59 (1992).
6. Brambell, F.W., Hemmings, W.A. & Morris, I.G. a theoretical model of gammaglobulin catabolism. Nature 203, 1352-1354 (1964).
7. Ghetie, V., Hubbard, J.G., Kim, J.K., Tsen, M.F., Lee, Y. & Ward, E.S. abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur. J. Immunol. 26, 690-696 (1996).
8. Junghans, R.P. & anderson, C.L. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl. Acad. Sci. U.S.A. 93, 5512-5516 (1996).
9. Israel, E.J., Wilsker, D.F., Hayes, K.C., Schoenfeld, D. & Simister, N.E. Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of fcRn. Immunology 89, 573-578 (1996).
10. Roopenian, D.C. et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, And fate of IgG-fc-coupled drugs. J. Immunol. 170, 3528-3533 (2003).
11. Chaudhury, C. et al. The major histocompatibility complex-related fc receptor for IgG (fcRn) binds albumin and prolongs its lifespan. J. Exp. Med. 197, 315-322 (2003).
12. Tabrizi, M.A., Tseng, C.M. & Roskos, L.K. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov. Today 11, 81-88 (2006).
13. Roskos, L.K., Davis, C.G. & Schwab, G.M. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev. Res. 61, 108-120 (2004).
14. Wang, W., Wang, E.Q. & Balthasar, J.P. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 84, 548-558 (2008).
15. Kuester, K., Kovar, A., Lüpfert, C., Brockhaus, B. & Kloft, C. Population pharmacokinetic data analysis of three phase I studies of matuzumab, A humanised anti-EGfR monoclonal antibody in clinical cancer development. Br. J. Cancer 98, 900-906 (2008).
16. Ng, C.M., Joshi, A., Dedrick, R.L., Garovoy, M.R. & Bauer, R.J. Pharmacokineticpharmacodynamic- efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm. Res. 22, 1088-1100 (2005).
17. Hinton, P.R., Xiong, J.M., Johlfs, M.G., Tang, M.T., Keller, S. & Tsurushita, N. an engineered human IgG1 antibody with longer serum half-life. J. Immunol. 176, 346-356 (2006).
18. Deng, R. et al. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal fc receptor variants in mice and cynomolgus monkeys. Drug Metab. Dispos. 38, 600-605 (2010).
19. Dall'acqua, W.F., Kiener, P.A. & Wu, H. Properties of human IgG1s engineered for enhanced binding to the neonatal fc receptor (fcRn). J. Biol. Chem. 281, 23514-23524 (2006).
20. Yeung, Y.A. et al. a therapeutic anti-VEGf antibody with increased potency independent of pharmacokinetic half-life. Cancer Res. 70, 3269-3277 (2010).
21. Mould, D.R. et al. a population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis. Clin. Pharmacol. Ther. 66, 246-257 (1999).
22. Mason, U. et al. CD4 coating, But not CD4 depletion, Is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. J. Rheumatol. 29, 220-229 (2002).
23. Choy, E.H. et al. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens. Arthritis Rheum. 39, 52-56 (1996).
24. Corper, A.L. et al. Structure of human IgM rheumatoid factor fab bound to its autoantigen IgG fc reveals a novel topology of antibody-antigen interaction. Nat. Struct. Biol. 4, 374-381 (1997).
25. Artandi, S.E., Calame, K.L., Morrison, S.L. & Bonagura, V.R. Monoclonal IgM rheumatoid factors bind IgG at a discontinuous epitope comprised of amino acid loops from heavy-chain constant-region domains 2 and 3. Proc. Natl. Acad. Sci. U.S.A. 89, 94-98 (1992).
26. Sasso, E.H., Barber, C.V., Nardella, F.A., Yount, W.J. & Mannik, M. antigenic specificities of human monoclonal and polyclonal IgM rheumatoid factors. The C gamma 2-C gamma 3 interface region contains the major determinants. J. Immunol. 140, 3098-3107 (1988).
27. Gibiansky, L., Gibiansky, E., Kakkar, T. & MA, P. approximations of the targetmediated drug disposition model and identifiability of model parameters. J. Pharmacokinet. Pharmacodyn. 35, 573-591 (2008).
28. Keizer, R.J., Huitema, A.D., Schellens, J.H. & Beijnen, J.H. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet. 49, 493-507 (2010).
29. Lebsack, M.E., Hanna, R.K., Lange, M.A. Newman, A., Ji, W. & Korth-Bradley, J.M. absolute bioavailability of TNf receptor fusion protein following subcutaneous injection in healthy volunteers. Pharmacotherapy 17, 1118-1119 (1997).
30. D'argenio, D.Z. & Schumitzky, A. ADAPT II Users Guide: Pharmacokinetic/ Pharmacodynamic System Analysis Software (Biomedical Simulations Resources, Los angeles, Ca, 1997).
31. Bauer R.J. & Guzy S. Monte Carlo parametric expectation maximization (MC-PEM) method for analyzing population pharmacokinetic/ pharmacodynamic (PK/PD) data. In: Advanced Methods of Pharmacokinetic and Pharmacodynamic System Analysis, Vol. 3,135-163 (Kluwer academic Publishers, Boston, Ma, 2004).
32. Ahn, J.E., Karlsson, M.O., Dunne, A. & Ludden, T.M. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J. Pharmacokinet. Pharmacodyn. 35, 401-421 (2008).